Entheogen Biotech's mission is to supply natural psychedelic compounds to worldwide clinical studies which are currently and almost exclusively using synthetic compounds, and to support the advancement of clinical research in mental health for institutions primarily seeking traditional regulatory-approval pathways for psychedelics including psilocybin and psilocin.
Our unparalleled (patent pending) cultivation technique is transformational and positions us to be the only/leading supplier of natural psilocybin and psilocin compounds in scale and consistent potency from our euGMP laboratory located in Jamaica. Entheogen is a Canadian controlled corporation constituted in 2021.
Entheogen launched its Jamaican laboratory in 2018 which operates under euGMP standards. Our team of PhDs utilized proprietary cultivation techniques (patent(s) pending with genome biomarkers) in the development of proprietary and industry leading intensive breeding of fungi compounds with a focus on APIs in the cultivation of psilocibin and psilocin.
​
Entheogen research is ongoing with non-psychoactive compounds.
​​
Our team of mycologists are currently advancing compound delivery by moderation of the pharmacokinetics to have a superior pharmacodynamic response or the effect of a compound on the body and the kinetics of absorption, distribution, metabolism and excretion.